Skip to main content
Disciplines
Automotive Business IT + Informatics Construction + Real Estate Electrical Engineering + Electronics Energy + Sustainability Insurance + Risk Finance + Banking Management + Leadership Marketing + Sales Mechanical Engineering + Materials
Events
DE
EN
Books
Journals
Topic Page
Marketing
Start single access now
Access for companies
EXTENDED SEARCH
Log in
Top
Published in:
Modelling of Heterostructures for Low Dimensional Devices Read chapter Read first chapter

2016 | OriginalPaper | Chapter

23. Nanomedicine

Authors : Eda Tahir Turanlı, Elif Everest

Published in: Low-Dimensional and Nanostructured Materials and Devices

Publisher: Springer International Publishing

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Nanomedicine is application of nanotechnology to diagnosis, treatment and prevention of diseases, in which multidisciplinary approaches are used combining chemistry, physics, biology, genetics, and medicine. Currently, there are a number of approved nanomedicines some of which have been developed to treat diseases using two main different approaches; passive or active targeting. Others include in vitro and in vivo diagnostic nanoparticles that have been shown to have many advantages compared to the traditional methods. Although there are some safety issues regarding development and use of nanoparticles in medicine and controversies surrounding the need for nanomedicine-specific regulations; many nanomedicines have been approved to date, and further improvements are being pursued with promising success. In this chapter, we summarise the use, advantages, current and future statuses of pharmaceutical and diagnostic nanomedicines, including ethical issues and regulations.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

inform now
previous chapter Quantum Dots in Bionanotechnology and Medical Sciences: Power of the Small
next chapter Microfluidics and Its Applications in Bionanotechnology
Literature
1.
2.
V. Wagner, B. Hüsing, S. Gaisser, Nanomedicine: Drivers for development and possible impacts. European Commission’s (EC) Joint Research Centre (JRC) Report No. 46744, 1–116 (2008)
3.
G. Gregoriadis, B.E. Ryman, Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem. J. 124, 58P (1971)
4.
P.D. Brown, P.R. Patel, Nanomedicine: a pharma perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7, 125–130 (2015)
5.
6.
7.
8.
9.
10.
F.S. Collins, We need better drugs—now. TEDMed Conference (Long Beach, CA, USA, 2012)
11.
T. Bartfai, G.V. Lees, The Future of Drug Discovery: Who Decides which Diseases to Treat? (Academic Press, 2013)
12.
D.T. Okuda, A. Siva, O. Kantarci, M. Inglese, I. Katz, M. Tutuncu, B.M. Keegan, S. Donlon, H. Hua le, A. Vidal-Jordana, X. Montalban, A. Rovira, M. Tintoré, M.P. Amato, B. Brochet, J. de Seze, D. Brassat, P. Vermersch, N. De Stefano, M.P. Sormani, D. Pelletier, C. Lebrun, Radiologically Isolated Syndrome Consortium (RISC), Club Francophone de la Sclérose en Plaques (CFSEP) Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One 9, e90509 (2014)
13.
Y. Matsumura, H. Maeda, A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent smancs. Cancer Res. 6, 6387–6392 (1986)
14.
Y. Barenholz, Doxil®—the first FDA-approved nano-drug: lessons learned. J. Control Releas. 160, 117–134 (2012)
15.
J. Vaage, E. Barberá-Guillem, R. Abra, A. Huang, P. Working, Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73, 1478–1484 (1994)
16.
A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, Y. Barenholz,  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987–992 (1994)
17.
L.W. Seymour, D.R. Ferry, D. Anderson, S. Hesslewood, P.J. Julyan, R. Poyner, J. Doran, A.M. Young, S. Burtles, D.J. Kerr, Cancer Research Campaign Phase I/II Clinical Trials committee, Hepatic drug targeting: phase I evaluation of polymer bound doxorubicin. J. Clin. Oncol. 20, 1668–1676 (2002)
18.
B. Wood, R.T.P. Poon, Z. Neeman, M. Eugeni, J. Locklin, S. Dromi, S. Kachala, R. Probhakar, W. Hahne, S.K. Libutti, Phase I study of thermally sensitive liposomes containing doxorubicin (ThermoDox [TD]) given during radiofrequency ablation (RFA) in patients with unresectable hepatic malignancies. ASCO Gastrointestinal Cancers Symposium (2007). abstr. 188
19.
20.
D. Sarker, P. Workman (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213–268 
21.
S.L. Stott, C.H. Hsu, D.I. Tsukrov, M. Yu, D.T. Miyamoto, B.A. Waltman, S.M. Rothenberg, A.M. Shah, M.E. Smas, G.K. Korir, F.P. Jr Floyd, A.J. Gilman, J.B. Lord, D. Winokur, S. Springer, D. Irimia, S. Nagrath, L.V. Sequist, R.J. Lee, K.J. Isselbacher, S. Maheswaran, D.A. Haber, M. Toner, Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. 107, 18392–18397 (2010)
22.
M.S. Muthu, S.A. Kulkarni, A. Raju, S.S. Feng, Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 33, 3494–3501 (2012)
23.
G. Oberdörster, Pulmonary effects of inhaled ultrafine particles. Int. Arch. Occup. Environ. Health 74, 1–8 (2001)
24.
P. Jani, G.W. Halbert, J. Langridge, A.T. Florence, Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42, 821–826 (1990)
25.
J. Lademann, H. Weigmann, C. Rickmeyer, H. Barthelmes, H. Schaefer, G. Mueller, W. Sterry, Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol. Appl. Skin Physiol. 12, 247–256 (1999)
26.
G. Oberdörster, Z. Sharp, V. Atudorei, A. Elder, R. Gelein, A. Lunts, W. Kreyling, C. Cox, Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J. Toxicol. Environ. Health A 65, 1531–1543 (2002)
27.
R. Gaspar, R. Duncan, Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 61, 1220–1231 (2009)
28.
M. Eaton, Nanomedicine: industry-wise research. Nat. Mater. 6, 251–253 (2007)
29.
R. Nijhara, K. Balakrishnan, Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomed 2, 127–136 (2006)
Metadata
Title
Nanomedicine
Authors
Eda Tahir Turanlı
Elif Everest
Copyright Year
2016
Book
Low-Dimensional and Nanostructured Materials and Devices

Print ISBN: 978-3-319-25338-1

Electronic ISBN: 978-3-319-25340-4

Copyright Year: 2016

DOI
https://doi.org/10.1007/978-3-319-25340-4_23

Premium Partners

    Image Credits